154 related articles for article (PubMed ID: 19550421)
1. Epstein-Barr virus antibody level and gastric cancer risk in Korea: a nested case-control study.
Kim Y; Shin A; Gwack J; Ko KP; Kim CS; Park SK; Hong YC; Kang D; Yoo KY
Br J Cancer; 2009 Aug; 101(3):526-9. PubMed ID: 19550421
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus-specific antibodies in Epstein-Barr virus-positive and -negative gastric carcinoma cases in Japan.
Shinkura R; Yamamoto N; Koriyama C; Shinmura Y; Eizuru Y; Tokunaga M
J Med Virol; 2000 Apr; 60(4):411-6. PubMed ID: 10686024
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the abbot Architect(™) epstein-barr virus viral capsid antigen IgM, viral capsid antigen IgG and nuclear antigen IgG assays in a pediatric and adult population.
Grandjean Lapierre S; Vallières E; Rabaamad L; Labrecque M; Chartrand C; Renaud C
J Clin Virol; 2016 Aug; 81():1-5. PubMed ID: 27258036
[TBL] [Abstract][Full Text] [Related]
4. Elevated antibody titers to Epstein-Barr virus prior to the diagnosis of Epstein-Barr-virus-associated gastric adenocarcinoma.
Levine PH; Stemmermann G; Lennette ET; Hildesheim A; Shibata D; Nomura A
Int J Cancer; 1995 Mar; 60(5):642-4. PubMed ID: 7860138
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis.
Nystad TW; Myrmel H
J Clin Virol; 2007 Apr; 38(4):292-7. PubMed ID: 17336144
[TBL] [Abstract][Full Text] [Related]
6. Evaluation the Architect EBV VCA IgM, VCA IgG, and EBNA-1 IgG chemiluminescent immunoassays to assess EBV serostatus prior transplantation.
Maylin S; Feghoul L; Salmona M; Herda A; Mercier-Delarue S; Simon F; Legoff J
J Med Virol; 2017 Nov; 89(11):2003-2010. PubMed ID: 28661055
[TBL] [Abstract][Full Text] [Related]
7. Multiple sclerosis and Epstein-Barr virus.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2003 Mar; 289(12):1533-6. PubMed ID: 12672770
[TBL] [Abstract][Full Text] [Related]
8. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.
Farrell RA; Antony D; Wall GR; Clark DA; Fisniku L; Swanton J; Khaleeli Z; Schmierer K; Miller DH; Giovannoni G
Neurology; 2009 Jul; 73(1):32-8. PubMed ID: 19458321
[TBL] [Abstract][Full Text] [Related]
9. Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis.
Levin LI; Munger KL; Rubertone MV; Peck CA; Lennette ET; Spiegelman D; Ascherio A
JAMA; 2005 May; 293(20):2496-500. PubMed ID: 15914750
[TBL] [Abstract][Full Text] [Related]
10. Circulating Antibodies against Epstein-Barr Virus (EBV) and p53 in EBV-Positive and -Negative Gastric Cancer.
Camargo MC; Kim KM; Matsuo K; Torres J; Liao LM; Morgan D; Michel A; Waterboer T; Song M; Gulley ML; Dominguez RL; Yatabe Y; Kim S; Cortes-Martinez G; Lissowska J; Zabaleta J; Pawlita M; Rabkin CS
Cancer Epidemiol Biomarkers Prev; 2020 Feb; 29(2):414-419. PubMed ID: 31719065
[TBL] [Abstract][Full Text] [Related]
11. Measurement of EBV-IgG anti-VCA avidity aids the early and reliable diagnosis of primary EBV infection.
Robertson P; Beynon S; Whybin R; Brennan C; Vollmer-Conna U; Hickie I; Lloyd A
J Med Virol; 2003 Aug; 70(4):617-23. PubMed ID: 12794726
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma.
Cai YL; Li J; Lu AY; Zheng YM; Zhong WM; Wang W; Gao JQ; Zeng H; Cheng JR; Tang MZ
Asian Pac J Cancer Prev; 2014; 15(5):2001-6. PubMed ID: 24716925
[TBL] [Abstract][Full Text] [Related]
13. Serological response to Epstein-Barr virus early antigen is associated with gastric cancer and human immunodeficiency virus infection in Zambian adults: a case-control study.
Kayamba V; Monze M; Asombang AW; Zyambo K; Kelly P
Pan Afr Med J; 2016; 23():45. PubMed ID: 27217871
[TBL] [Abstract][Full Text] [Related]
14. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
Xia C; Zhu K; Zheng G
Int J Clin Exp Pathol; 2015; 8(12):16104-10. PubMed ID: 26884888
[TBL] [Abstract][Full Text] [Related]
15. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
[TBL] [Abstract][Full Text] [Related]
16. Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen.
Persson Berg L; Thomsson E; Hasi G; Bäckström M; Bergström T
J Virol Methods; 2020 Oct; 284():113927. PubMed ID: 32650039
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study.
Ascherio A; Munger KL; Lennette ET; Spiegelman D; Hernán MA; Olek MJ; Hankinson SE; Hunter DJ
JAMA; 2001 Dec; 286(24):3083-8. PubMed ID: 11754673
[TBL] [Abstract][Full Text] [Related]
18. A systematic study of Epstein-Barr virus serologic assays following acute infection.
Rea TD; Ashley RL; Russo JE; Buchwald DS
Am J Clin Pathol; 2002 Jan; 117(1):156-61. PubMed ID: 11789721
[TBL] [Abstract][Full Text] [Related]
19. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].
Cai YL; Zheng YM; Cheng JR; Wang W; Zhang YN; Wang WH; Wu YS; Zhong WM; Li J; Mo YK
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus serology and gastric cancer incidence and survival.
Koshiol J; Qiao YL; Mark SD; Dawsey SM; Abnet CC; Kamangar F; Lennette ET; Dong ZW; Taylor PR
Br J Cancer; 2007 Dec; 97(11):1567-9. PubMed ID: 17987041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]